Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Prospective Qualitative Study Concerning the Efficiency of PBSC Collections after a Change of Apheresis Device

Marie Y. Detrait, MD, Stephane Morisset, Stat., Jean-Pierre Delville, Arnaud Lixon, Julie Boul, Jean-François Colot, Sabine Meurisse, Odile Bocahut, Philippe Mineur, MD, Margareta Nedelcu, Delphine Pranger, Julien Depaus, Carmela Piacentini, Maryvonne Jurdan, MD, Anne Kornreich, MD, Jean-Luc Canon

Blood (2014) 124 (21): 5834.

https://doi.org/10.1182/blood.V124.21.5834.5834

Published: 2014

Journal Articles

Invasive Pulmonary Aspergillosis in AML and ALL Patients Hospitalized into an Intensive Care Unit Divided into 2 Areas with a Different Specific Air Environment: Evaluation of Posaconazole Prophylaxis and Comparison Between the Two Specific Air Environment Areas

Marie Y. Detrait, MD, Stephane Morisset, Stat., Jean-Pierre Delville, Arnaud Lixon, Sabine Meurisse, Xavier Holemans, Nathalie De Visscher, Philippe Mineur, MD, Delphine Pranger, Margareta Nedelcu, Julien Depaus, Martin Di Biase, Celine Van Wetter, Francoise Anckaert, Anne Kornreich, MD, Jean-Luc Canon

Blood (2014) 124 (21): 5260.

https://doi.org/10.1182/blood.V124.21.5260.5260

Published: 2014

Journal Articles

Risk of Adverse Events Is Similar in Patients (Pts) Who Did or Did Not Achieve Hemoglobin (Hb) Above 12g/dL in a Phase 3 Clinical Trial of Darbepoetin alfa (DA) Administered Weekly (QW) or Every 3 Weeks (Q3W) in Anemic Cancer Pts Receiving Chemotherapy.

Heinz Ludwig, MD, Jean-Luc Canon, MD, Johan Vansteenkiste, MD, PhD, Lisa Hamilton, MSc, Tamás Suto, MD, PhD

Blood (2007) 110 (11): 4086.

https://doi.org/10.1182/blood.V110.11.4086.4086

Published: 2007

Journal Articles

Evaluation of Hematologic Endpoints Used To Assess Erythropoiesis-Stimulating Agents (ESAs): A Pooled Analysis of Data from over 10,000 Patients (pts) with Chemotherapy-Induced Anemia (CIA).

John Glaspy, David H. Henry, Jean-Luc Canon, Hung Lam, Tom Lillie

Blood (2006) 108 (11): 3764.

https://doi.org/10.1182/blood.V108.11.3764.3764

Published: 2006

Journal Articles

Effects of Dose Adjustment Rules on Safety during Erythropoietic Therapy: A Retrospective Analysis of Darbepoetin alfa Administered Either Every 3 Weeks or Weekly.

Michael Hedenus, Jean-Luc Canon, Dusan Kotasek, Tom Lillie, Lisa Hendricks, Bin Yao, Johan Vansteenkiste

Blood (2005) 106 (11): 3376.

https://doi.org/10.1182/blood.V106.11.3376.3376

Published: 2005

Journal Articles

Effect of Dose Reductions on Response to 500-μg Darbepoetin alfa Administered Once Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia: Analysis from a Randomized, Double-Blind, Active-Controlled Trial.

Jean-Luc Canon, MD, Johan Vansteenkiste, MD, Gyorgy Bodoky, MD, Ma Victoria Mateos, MD, Laurent Bastit, MD, Irene Ferreira, PhD, Tom Lillie, MD

Blood (2005) 106 (11): 3558.

https://doi.org/10.1182/blood.V106.11.3558.3558

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Prospective Qualitative Study Concerning the Efficiency of PBSC Collections after a Change of Apheresis Device

Invasive Pulmonary Aspergillosis in AML and ALL Patients Hospitalized into an Intensive Care Unit Divided into 2 Areas with a Different Specific Air Environment: Evaluation of Posaconazole Prophylaxis and Comparison Between the Two Specific Air Environment Areas

Risk of Adverse Events Is Similar in Patients (Pts) Who Did or Did Not Achieve Hemoglobin (Hb) Above 12g/dL in a Phase 3 Clinical Trial of Darbepoetin alfa (DA) Administered Weekly (QW) or Every 3 Weeks (Q3W) in Anemic Cancer Pts Receiving Chemotherapy.

Evaluation of Hematologic Endpoints Used To Assess Erythropoiesis-Stimulating Agents (ESAs): A Pooled Analysis of Data from over 10,000 Patients (pts) with Chemotherapy-Induced Anemia (CIA).

Effects of Dose Adjustment Rules on Safety during Erythropoietic Therapy: A Retrospective Analysis of Darbepoetin alfa Administered Either Every 3 Weeks or Weekly.

Effect of Dose Reductions on Response to 500-μg Darbepoetin alfa Administered Once Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia: Analysis from a Randomized, Double-Blind, Active-Controlled Trial.

Email alerts

ASH Publications

American Society of Hematology

Update search

Prospective Qualitative Study Concerning the Efficiency of PBSC Collections after a Change of Apheresis Device

Invasive Pulmonary Aspergillosis in AML and ALL Patients Hospitalized into an Intensive Care Unit Divided into 2 Areas with a Different Specific Air Environment: Evaluation of Posaconazole Prophylaxis and Comparison Between the Two Specific Air Environment Areas

Risk of Adverse Events Is Similar in Patients (Pts) Who Did or Did Not Achieve Hemoglobin (Hb) Above 12g/dL in a Phase 3 Clinical Trial of Darbepoetin alfa (DA) Administered Weekly (QW) or Every 3 Weeks (Q3W) in Anemic Cancer Pts Receiving Chemotherapy.

Evaluation of Hematologic Endpoints Used To Assess Erythropoiesis-Stimulating Agents (ESAs): A Pooled Analysis of Data from over 10,000 Patients (pts) with Chemotherapy-Induced Anemia (CIA).

Effects of Dose Adjustment Rules on Safety during Erythropoietic Therapy: A Retrospective Analysis of Darbepoetin alfa Administered Either Every 3 Weeks or Weekly.

Effect of Dose Reductions on Response to 500-μg Darbepoetin alfa Administered Once Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia: Analysis from a Randomized, Double-Blind, Active-Controlled Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only